PDLI · CIK 882104
What PDL BioPharma, Inc. told the SEC could break it.
PDL's value rests entirely on a portfolio of royalty rights tied to third-party pharmaceutical and device products (such as Assertio, Noden/Tekturna and Paradigm Spine), whose cash flows can erode from generic competition, shifts in market size or share, pricing and reimbursement changes, or approval delays. That value is being returned to shareholders rather than grown: the company is winding down under a Plan of Dissolution, reporting on a liquidation basis, so the precise amount and timing of distributions is uncertain and could be delayed or reduced by creditor claims and reserve adequacy under the court order. Its royalty income also hinges on outside parties and policy — its licensees must maintain FDA approvals for their products, and U.S. political pressure to cut drug prices could lower the royalties underlying its assets.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- royalty-asset portfolio exposed to generic competition, pricing and reimbursement changeshigh
PDL's value rests on royalty rights tied to third-party pharma/device products (e.g. Assertio, Noden/Tekturna, Paradigm Spine), whose cash flows can fall from generic competition, market-size/share shifts, pricing-strategy or reimbursement changes, and approval delays.
“Factors that could cause a change in estimates of future cash flows include a change in estimated market size, market share of the products on which we receive royalties, a change in pricing strategy or reimbursement coverage, a delay in obtaining regulatory approval, changes to forecast volume and pricing as a result of generic competition, a change in dosage of the product, and a change in the number of treatments.”
SEC filing →As of 2021 - Plan of Dissolution / going-concern liquidation; uncertain timing and amount of stockholder distributionsmedium
PDL is winding down under a Plan of Dissolution (reporting on a Going Concern/liquidation basis), so the precise amount and timing of distributions to stockholders is uncertain and could be delayed or diminished by claim resolutions, creditor disputes and reserve adequacy under the Court Order.
“The precise amount and timing of any distributions to our stockholders will depend on and could be delayed or diminished due to many factors, including without limitation: whether a claim is resolved for more than the amount of reserve established for such claim pursuant to the Court Order; whether we are unable to resolve claims with creditors or other third parties, or if”
Regulatory & policy
- FDA approval-maintenance by licensees and US drug-pricing pressure on royalty productsmedium
PDL's royalty income depends on its licensees/counterparties maintaining FDA approvals for their products, and on the US drug-pricing environment — political focus on reducing pharmaceutical prices could lower the royalty revenue underlying PDL's assets.
“Our licensees, borrowers and royalty-agreement counterparties may not maintain necessary regulatory approvals for their existing products. Moreover, the current political environment in the United States is focused on potential reductions in pricing for pharmaceutical and other healthcare products, which may negatively impact any existing or new products from which our revenues would be”
SEC filing →As of 2021
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch